Globe Newswire

NASSAU, The Bahamas, June 01, 2024 (GLOBE NEWSWIRE) -- OKX, a leading crypto exchange by trading volume and a leading Web3 technology company, has issued updates for June 1, 2024.

OKX Announces Position Tier Adjustments for TURBO/USDT Perpetual Futures ListingIn a continuous effort to enhance market liquidity and mitigate risks, OKX has announced that it will be making adjustments to the position tiers of its TURBO/USDT perpetual futures listing.

This action... (continue reading...)

-  WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy -

-  Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete response -

-  Monotherapy recommended dose for expansion selected and expansion arms open for enrollment -

-  Preliminary data on WTX-124 administered to patients in combination with... (continue reading...)

Newly Launched Technology Will Be on Display at ASSFN in Nashville from June 1 - 4

SOLANA BEACH, Calif., June 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announces full market release of its SmartFrame OR platform and ClearPoint Prism Neuro Laser Therapy System at the 2024 Biennial Meeting of the American Society... (continue reading...)

SAN DIEGO, June 01, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fastly, Inc. (NYSE: FSLY) securities between February 15, 2024 and May 1, 2024, both dates inclusive (the “Class Period”), have until July 23, 2024 to seek appointment as lead plaintiff of the Fastly class action lawsuit. Captioned Kula v. Fastly, Inc., No. 24-cv-03170 (N.D. Cal.), the Fastly class action lawsuit charges Fastly and certain of... (continue reading...)

NON-REGULATORY PRESS RELEASE

Oslo, June 1, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (NCT04382664), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. The late-breaking abstract can be found on the 2024 ASCO website:... (continue reading...)